This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carducci, M. A. Articles by Nelson, J. B. Search for Related Content PubMed PubMed Citation Articles by Carducci, M. A. Articles by Nelson, J. B. Social Bookmarking                            What's this?

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Michael A. Carducci, Robert J. Padley, Jurgen Breul, Nicholas J. Vogelzang, Bernard A. Zonnenberg, Danai D. Daliani, Claude C. Schulman, Azmi A. Nabulsi, Rod A. Humerickhouse, Mark A. Weinberg, Jennifer L. Schmitt, Joel B. Nelson

From the Sidney Kimmel Comprehensive Cancer Center, the Johns Hopkins University School of Medicine, Baltimore, MD; Abbott Laboratories, Abbott Park, IL; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany; Department of Medicine, Section of Hematology/Oncology and the Cancer Research Center, University of Chicago, Chicago, IL; Department of Medical Oncology, University Medical Center, Utrecht, the Netherlands; Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Department of Urology, University Hospital Erasme, Brussels, Belgium.

Address reprint requests to Joel B. Nelson, MD, University of Pittsburgh School of Medicine, 5200 Centre Ave, Pittsburgh, PA 15232; email: nelsonjb{at}msx.upmc.edu.

Purpose: To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of asymptomatic, hormone-refractory prostatic adenocarcinoma.

Patients and Methods: A double-blind, randomized, placebo-controlled clinical trial of hormone-refractory prostate cancer (HRPCa) patients was conducted in the United States and Europe. Two hundred eighty-eight asymptomatic patients with HRPCa and evidence of metastatic disease were randomly assigned to one of three study groups receiving a once-daily oral dose of placebo, 2.5 mg atrasentan, or 10 mg atrasentan, respectively. Primary end point was time to progression; secondary end points included time to prostate-specific antigen (PSA) progression, bone scan changes, and changes in bone and tumor markers.

Results: The three treatment groups were similar in all baseline characteristics. Median time to progression in intent-to-treat (ITT) patients (n = 288) was longer in the 10-mg atrasentan group compared with the placebo group: 183 v 137 days, respectively; (P = .13). Median time to progression in evaluable patients (n = 244) was significantly prolonged, from 129 days (placebo group) to 196 days (10-mg atrasentan group; P = .021). For both ITT and evaluable populations in the 10-mg atrasentan group, median time to PSA progression was twice that of the placebo group (155 v 71 days; P = .002). Patients who received placebo continued to have significant increases from baseline in serum (lactate dehydrogenase [LDH]), a marker of disease burden; elevations in LDH were uniformly attenuated by atrasentan in the ITT population. Headache, peripheral edema, and rhinitis were primary side effects, typically of mild to moderate severity. Quality of life was not adversely affected by atrasentan.

Conclusion: Atrasentan is an oral, targeted therapy with favorable tolerability and the potential to delay progression of HRPCa.

Supported by a grant from Abbott Laboratories, Abbott Park, IL. N.J. Vogelzang was supported in part by grant no. P30-CA-14599 from the National Institutes of Health, Department of Health and Human Services, Bethesda, MD. M.A. Carducci and J.B. Nelson were supported in part by NIH/NCI grant no. K08-CA-69164 from the National Cancer Institute, National Institutes of Health, and by the Association for the Cure of Cancer of the Prostate, Santa Monia, CA.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. D. McGoon, A. E. Frost, R. J. Oudiz, D. B. Badesch, N. Galie, H. Olschewski, V. V. McLaughlin, M. J. Gerber, C. Dufton, D. J. Despain, et al. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities Chest, January 1, 2009; 135(1): 122 - 129. [Abstract] [Full Text] [PDF]

				A. B. Apolo, N. Pandit-Taskar, and M. J. Morris Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer J. Nucl. Med., December 1, 2008; 49(12): 2031 - 2041. [Abstract] [Full Text] [PDF]

				S. Phuphanich, K. A. Carson, S. A. Grossman, G. Lesser, J. Olson, T. Mikkelsen, S. Desideri, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy (NAB Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma Neuro-oncol, August 1, 2008; 10(4): 617 - 623. [Abstract] [Full Text] [PDF]

				C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378. [Abstract] [Full Text] [PDF]

				H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group J. Clin. Oncol., March 1, 2008; 26(7): 1148 - 1159. [Abstract] [Full Text] [PDF]

				A. A. Chiappori, E. Haura, F. A. Rodriguez, D. Boulware, R. Kapoor, A. M. Neuger, R. Lush, B. Padilla, M. Burton, C. Williams, et al. Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1464 - 1469. [Abstract] [Full Text] [PDF]

				F. E. Lecouvet, D. Geukens, A. Stainier, F. Jamar, J. Jamart, B. J. d'Othee, P. Therasse, B. V. Berg, and B. Tombal Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies J. Clin. Oncol., August 1, 2007; 25(22): 3281 - 3287. [Abstract] [Full Text] [PDF]

				K. Lange, M. Kammerer, M. E. Hegi, S. Grotegut, A. Dittmann, W. Huang, E. Fluri, G. W. Yip, M. Gotte, C. Ruiz, et al. Endothelin Receptor Type B Counteracts Tenascin-C-Induced Endothelin Receptor Type A-Dependent Focal Adhesion and Actin Stress Fiber Disorganization Cancer Res., July 1, 2007; 67(13): 6163 - 6173. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Warren, and G. Heller The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492. [Abstract] [Full Text] [PDF]

				G. A. Clines, K. S. Mohammad, Y. Bao, O. W. Stephens, L. J. Suva, J. D. Shaughnessy Jr., J. W. Fox, J. M. Chirgwin, and T. A. Guise Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation Mol. Endocrinol., February 1, 2007; 21(2): 486 - 498. [Abstract] [Full Text] [PDF]

				C. Van Sant, G. Wang, M. G. Anderson, O. J. Trask, R. Lesniewski, and D. Semizarov Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway Mol. Cancer Ther., January 1, 2007; 6(1): 253 - 261. [Abstract] [Full Text] [PDF]

				T. A. Guise, K. S. Mohammad, G. Clines, E. G. Stebbins, D. H. Wong, L. S. Higgins, R. Vessella, E. Corey, S. Padalecki, L. Suva, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res., October 15, 2006; 12(20): 6213s - 6216s. [Abstract] [Full Text] [PDF]

				R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]

				M. A. Carducci and A. Jimeno Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin. Cancer Res., October 15, 2006; 12(20): 6296s - 6300s. [Abstract] [Full Text] [PDF]

				C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]

				B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug. Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695. [Abstract] [Full Text] [PDF]

				C. P. Tarassoff, P. M. Arlen, and J. L. Gulley Therapeutic vaccines for prostate cancer. Oncologist, May 1, 2006; 11(5): 451 - 462. [Abstract] [Full Text] [PDF]

				A. Bagnato, F. Spinella, and L. Rosano Emerging role of the endothelin axis in ovarian tumor progression Endocr. Relat. Cancer, December 1, 2005; 12(4): 761 - 772. [Abstract] [Full Text] [PDF]

				R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241. [Abstract] [Full Text] [PDF]

				W. Berry and M. Eisenberger Achieving Treatment Goals for Hormone-Refractory Prostate Cancer with Chemotherapy Oncologist, October 1, 2005; 10(suppl_3): 30 - 39. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2 Cancer Res., August 15, 2005; 65(16): 7320 - 7327. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]

				A. Michael, G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables Clin. Cancer Res., June 15, 2005; 11(12): 4469 - 4478. [Abstract] [Full Text] [PDF]

				C. W. Ryan, N. J. Vogelzang, E. E. Vokes, H. L. Kindler, S. D. Undevia, R. Humerickhouse, A. K. Andre, Q. Wang, R. A. Carr, and M. J. Ratain Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies Clin. Cancer Res., July 1, 2004; 10(13): 4406 - 4411. [Abstract] [Full Text] [PDF]

				Y. Daaka G Proteins in Cancer: The Prostate Cancer Paradigm Sci. Signal., January 20, 2004; 2004(216): re2 - re2. [Abstract] [Full Text] [PDF]

				P. Wulfing, R. Diallo, C. Kersting, C. Wulfing, C. Poremba, A. Rody, R. R. Greb, W. Bocker, and L. Kiesel Expression of Endothelin-1, Endothelin-A, and Endothelin-B Receptor in Human Breast Cancer and Correlation with Long-Term Follow-Up Clin. Cancer Res., September 15, 2003; 9(11): 4125 - 4131. [Abstract] [Full Text] [PDF]

				V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]

				L. Rosano, F. Spinella, D. Salani, V. Di Castro, A. Venuti, M. R. Nicotra, P. G. Natali, and A. Bagnato Therapeutic Targeting of the Endothelin A Receptor in Human Ovarian Carcinoma Cancer Res., May 15, 2003; 63(10): 2447 - 2453. [Abstract] [Full Text] [PDF]

				E. Baldi, L. Bonaccorsi, and G. Forti Androgen Receptor: Good Guy or Bad Guy in Prostate Cancer Invasion? Endocrinology, May 1, 2003; 144(5): 1653 - 1655. [Full Text] [PDF]